Skip to main content

Table 1 Patient characteristics

From: Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

  Total Non-CKD CKD group Subtotal of CKD groups P value*
Mild CKD Moderate CKD Severe CKD
n = 241 n = 87 n = 93 n = 43 n = 18 n = 154
Age, y (mean ± SD) 64.1 ± 21.7 50.2 ± 20.8 65.5 ± 19.2 82.2 ± 9.6 81.2 ± 10.2 72.0 ± 18.0 <0.001
Male, n (%) 143 (59.3%) 53 (60.9%) 58 (62.4%) 21 (48.8%) 11 (61.1%) 90 (58.4%) 0.488
BMI, kg/m2 (mean ± SD) 19.0 ± 2.4 19.1 ± 2.0 19.1 ± 2.6 18.9 ± 2.7 18.3 ± 2.9 19.0 ± 2.6 0.517
Body weight, kg (range) 27.8–64.4 30.8–60.0 27.8–60.0 30.0–60.0 31.5–64.4 27.8–64.4
Current or ex-smoker, n (%) 99 (41.1%) 38 (43.7%) 41 (44.1%) 13 (30.2%) 7 (38.9%) 61 (39.6%) 0.438
Past history of TB treatment, n (%) 69 (28.6%) 14 (16.1%) 31 (33.3%) 20 (46.5%) 4 (22.2%) 55 (35.7%) 0.002
Underlying disease
 Diabetes mellitus 77 (32.0%) 30 (34.5%) 28 (30.1%) 14 (32.6%) 5 (27.8%) 47 (30.5%) 0.907
 Pulmonary disease 26 (10.8%) 7 (8.0%) 10 (10.8%) 4 (9.3%) 5 (27.8%) 19 (12.3%) 0.103
 Malignancy 20 (8.3%) 7 (8.0%) 7 (7.5%) 5 (11.6%) 1 (5.6%) 13 (8.4%) 0.829
 Liver damage 18 (7.5%) 6 (6.9%) 9 (9.7%) 2 (4.7%) 1 (5.6%) 12 (7.8%) 0.732
 Alcoholic liver disease 3 (1.2%) 1 (1.1%) 2 (2.2%) 0 (0%) 0 (0%) 2 (1.3%)
 Hepatitis C virus 3 (1.2%) 0 (0%) 1 (1.1%) 2 (4.7%) 0 (0%) 3 (1.9%)
 Autoimmune hepatitis 2 (0.8%) 0 (0%) 2 (2.2%) 0 (0%) 0 (0%) 2 (1.3%)
 Hepatitis B virus 1 (0.4%) 0 (0%) 1 (1.1%) 0 (0%) 0 (0%) 1 (0.6%)
 Others 9 (3.7%) 5 (5.7%) 3 (3.2%) 0 (0%) 1 (5.6%) 4 (2.6%)
Immunosuppressive drug use, n (%) 33 (13.7%) 8 (9.2%) 11 (11.8%) 12 (28.0%) 2 (11.1%) 25 (16.2%) 0.027
Sputum smear positive, n (%) 210 (87.1%) 78 (89.7%) 82 (88.2%) 41 (95.3%) 9 (50.0%) 132 (85.7%) <0.001
Cavitation on chest X-ray, n (%) 105 (43.6%) 54 (62.1%) 36 (38.7%) 11 (25.6%) 4 (22.2%) 51 (33.1%) <0.001
Laboratory data
 WBC count, cells/mL (mean ± SD) 7258 ± 2789 7492 ± 2440 7206 ± 2798 7121 ± 2612 6722 ± 4455 7126 ± 2968 0.705
 Lymphocyte, cells/mL (mean ± SD) 1054 ± 619 1180 ± 654 1120 ± 609 819 ± 485 667 ± 495 983 ± 588 <0.001
Albumin, g/dL (mean ± SD) 3.2 ± 0.8 3.4 ± 0.8 3.4 ± 0.7 2.9 ± 0.7 2.4 ± 0.9 3.1 ± 0.8 <0.001
Treatment regimen, n (%)
 HREZ 164 (68.0%) 75 (86.2%) 69 (74.2%) 15 (34.9%) 5 (27.8%) 89 (57.8%) < 0.001
 HRE 77 (32.0%) 12 (13.8%) 24 (25.8%) 28 (65.1%) 13 (72.2%) 65 (42.2%)
Treatment dosage, mg/kg (mean ± SD)  
 INH 5.6 ± 0.5 5.5 ± 0.5 5.6 ± 0.5 5.6 ± 0.5 5.4 ± 0.5 5.6 ± 0.5 0.689
 RMP 8.9 ± 1.2 8.8 ± 1.1 8.8 ± 1.1 9.3 ± 1.4 9.0 ± 1.4 9.0 ± 1.2 0.089
 EMB 14.3 ± 1.8 14.3 ± 1.6 14.6 ± 1.7 14.6 ± 1.6 12.6 ± 2.9 14.3 ± 2.0 <0.001
 PZA 23.3 ± 2.3 23.2 ± 2.1 23.3 ± 2.1 24.0 ± 3.0 23.5 ± 4.5 23.4 ± 2.4 0.692
  1. *One-way ANOVA or Chi-square test was used to compare for each parameter
  2. BMI body mass index, CKD chronic kidney disease, EMB ethambutol, HRE isoniazid: rifampicin and ethambutol, HREZ isoniazid, rifampicin, ethambutol and pyrazinamide, INH isoniazid; min, minimum; max, maximum, PZA pyrazinamide, RMP rifampicin, SD standard deviation, TB tuberculosis, WBC white blood cell